PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.21%
EBIT growth of 47.21% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
40.44%
Operating income growth of 40.44% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
42.50%
Net income growth of 42.50% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
40.54%
EPS growth of 40.54% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
40.54%
Diluted EPS growth of 40.54% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
0.40%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.40%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
51.97%
OCF growth of 51.97% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
51.97%
FCF growth of 51.97% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
95.95%
OCF/share CAGR of 95.95% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
79.78%
5Y OCF/share growth exceeding 1.5x Biotechnology median of 19.46%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
21.40%
3Y OCF/share growth 75-90% of Biotechnology median. John Neff would seek operational tweaks to match peers’ recent gains.
95.64%
Net income/share CAGR exceeding 1.5x Biotechnology median of 32.54% over a decade. Joel Greenblatt might see a standout compounder of earnings.
74.54%
5Y net income/share CAGR > 1.5x Biotechnology median of 34.54%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
42.66%
3Y net income/share CAGR 1.25-1.5x Biotechnology median. Mohnish Pabrai would confirm expansions or margin boosts drive the short-term advantage.
160.55%
Equity/share CAGR of 160.55% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
2.24%
5Y equity/share CAGR of 2.24% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-69.25%
Negative 3Y equity/share growth while Biotechnology median is -51.44%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts or stagnation while Biotechnology median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-14.61%
Negative BV/share change while Biotechnology median is -5.84%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.07%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-50.78%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-4.70%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.